There are 2773 resources available
75P - Tumor mutational burden in clinical routine practice: Identifying the right threshold?
Presenter: Célia Dupain
Session: ePoster Display
74P - A predictive signature for response to immunotherapy in non-small cell lung cancer based on plasma proteomics and clinical parameters
Presenter: Yuval Shaked
Session: ePoster Display
76P - Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
Presenter: Ana Oaknin
Session: ePoster Display
78P - Prognostic value of thyroid transcription factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
Presenter: Loïck Galland
Session: ePoster Display
79P - SETD2 a potential tissue-agnostic predictive biomarker for ICIs in solid tumors
Presenter: Yu Chen
Session: ePoster Display
80P - Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN
Presenter: Mishima Saori
Session: ePoster Display
81P - Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)
Presenter: Javier Garcia-Corbacho
Session: ePoster Display
83P - Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10
Presenter: Arlene Siefker-Radtke
Session: ePoster Display
84P - Metastatic mismatch repair deficiency cancers: Hard to find, but a delight to treat!
Presenter: Amit Rauthan
Session: ePoster Display
85P - Influence of different age cutoff points on the prediction of prognosis of cancer patients receiving ICIs and potential mechanistic exploration
Presenter: Qiong Lyu
Session: ePoster Display